Skip to main content

Table 5 Bleb failure risk factors and failure results per group

From: Preliminary results of Preserflo Microshunt versus Preserflo Microshunt and Ologen implantation

Demographics Group A Group B
No. of eyes operated total 25 25
Prior ocular surgeries Phacoemulsification Phacoemulsification
Ethnicity of patients Caucasian Caucasian
No. of female patients 18 15
Age (years) 77.58 ± 7.62 75.64 ± 12.61
No. of male patients 7 10
Bleb revision surgery at 6 months (failure rate) 1 (4%) 3 (12%)
  1. MMC mitomycin C
  2. Group A: Preserflo Microshunt with MMC 0.2 mg/ml
  3. Group B: Preserflo Microshunt with MMC 0.2 mg/ml and Ologen